Corrigendum to: Pooled analysis of tanezumab efficacy and safety with subgroup analyses of phase III clinical trials in patients with osteoarthritis pain of the knee or hip (J Pain Res. (2019), 12, (975—995), 10.2147/JPR.S191297);Pooled analysis of tanezumab efficacy and safety with subgroup analyses of phase iii clinical trials in patients with osteoarthritis pain of the knee or hip

Journal of Pain Research

Volumn 12, Issue , 2019, Pages 975-995

  Tive, Leslie ^a   Bello, Alfonso E ^b   Radin, David ^c   Schnitzer, Thomas J ^d   Nguyen, Ha ^a   Brown, Mark T ^a   West, Christine R ^a  

^a PFIZER INC   (United States)

^b ILLINOIS BONE AND JOINT INSTITUTE   (United States)

^c Stamford Therapeutics Consortium   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Efficacy; Nerve growth factor; Osteoarthritis; Safety; Tanezumab

Indexed keywords

CELECOXIB; DICLOFENAC; NAPROXEN; OXYCODONE; PLACEBO; TANEZUMAB;

ADULT; ADVERSE OUTCOME; ARTHRALGIA; ARTICLE; BRADYCARDIA; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DISEASE ASSESSMENT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HIP OSTEOARTHRITIS; HIP PAIN; HUMAN; HYPESTHESIA; KNEE OSTEOARTHRITIS; KNEE PAIN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; NAUSEA; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PARESTHESIA; PATIENT GLOBAL ASSESSMENT; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PHYSICAL PERFORMANCE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SENSORY DYSFUNCTION; VOMITING; WESTERN ONTARIO AND MCMASTER UNIVERSITIES OSTEOARTHRITIS INDEX;

EID: 85066752389     PISSN: None     EISSN: 11787090     Source Type: Journal    
DOI: 10.2147/JPR.S279856     Document Type: Erratum

References (40)

1. McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014;22(3):363–388.
2. Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2012;64(4):465–474.
3. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. 2008;16(2):137–162.
4. Kim J, Lee J, Shin CM, Lee DH, Park BJ. Risk of gastrointestinal bleeding and cardiovascular events due to NSAIDs in the diabetic elderly population. BMJ Open Diabetes Res Care. 2015;3(1):e000133.
5. Sowers JR, White WB, Pitt B, et al; Celecoxib Rofecoxib Efficacy and Safety in Comorbidities Evaluation Trial (CRESCENT) Investigators. The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med. 2005;165(2):161–168.
6. Wehling M. Non-steroidal anti-inflammatory drug use in chronic pain conditions with special emphasis on the elderly and patients with relevant comorbidities: management and mitigation of risks and adverse effects. Eur J Clin Pharmacol. 2014;70(10):1159–1172.
7. Abdiche YN, Malashock DS, Pons J. Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors. Protein Sci. 2008;17(8):1326–1335.
8. Hefti FF, Rosenthal A, Walicke PA, et al. Novel class of pain drugs based on antagonism of NGF. Trends Pharmacol Sci. 2006;27(2):85–91.
9. Mantyh PW, Koltzenburg M, Mendell LM, Tive L, Shelton DL. Antagonism of nerve growth factor-TrkA signaling and the relief of pain. Anesthesiology. 2011;115(1):189–204.
10. Balanescu AR, Feist E, Wolfram G, et al. Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial. Ann Rheum Dis. 2014;73(9):1665–1672.
11. Brown MT, Herrmann DN, Goldstein M, et al. Nerve safety of tanezumab, a nerve growth factor inhibitor for pain treatment. J Neurol Sci. 2014;345(1–2):139–147.
12. Brown MT, Murphy FT, Radin DM, Davignon I, Smith MD, West CR. Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trial. J Pain. 2012;13(8):790–798.
13. Brown MT, Murphy FT, Radin DM, Davignon I, Smith MD, West CR. Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial. Arthritis Rheum. 2013;65(7):1795–1803.
14. Ekman EF, Gimbel JS, Bello AE, et al. Efficacy and safety of intravenous tanezumab for the symptomatic treatment of osteoarthritis: 2 randomized controlled trials versus naproxen. J Rheumatol. 2014;41(11):2249–2259.
15. Evans RJ, Moldwin RM, Cossons N, Darekar A, Mills IW, Scholfield D. Proof of concept trial of tanezumab for the treatment of symptoms associated with interstitial cystitis. J Urol. 2011;185(5):1716–1721.
16. Gimbel JS, Kivitz AJ, Bramson C, et al. Long-term safety and effectiveness of tanezumab as treatment for chronic low back pain. Pain. 2014;155(9):1793–1801.
17. Katz N, Borenstein DG, Birbara C, et al. Efficacy and safety of tanezumab in the treatment of chronic low back pain. Pain. 2011;152(10): 2248–2258.
18. Kivitz AJ, Gimbel JS, Bramson C, et al. Efficacy and safety of tanezumab versus naproxen in the treatment of chronic low back pain. Pain. 2013;154(7):1009–1021.
19. Lane NE, Schnitzer TJ, Birbara CA, et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med. 2010;363(16):1521–1531.
20. Nagashima H, Suzuki M, Araki S, Yamabe T, Muto C; Tanezumab Investigators. Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized, double-blind, dose-escalation, placebo-controlled study. Osteoarthritis Cartilage. 2011;19(12):1405–1412.
21. Schnitzer TJ, Ekman EF, Spierings EL, et al. Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain. Ann Rheum Dis. 2015;74(6):1202–1211.
22. Schnitzer TJ, Lane NE, Birbara C, Smith MD, Simpson SL, Brown MT. Long-term open-label study of tanezumab for moderate to severe osteoarthritic knee pain. Osteoarthritis Cartilage. 2011;19(6): 639–646.
23. Spierings EL, Fidelholtz J, Wolfram G, Smith MD, Brown MT, West CR. A phase III placebo-and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee. Pain. 2013;154(9):1603–1612.
24. Spierings EL, Fidelholtz J, Wolfram G, Smith MD, Brown MT, West CR. A phase III placebo-and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee: response. Pain. 2014;155(11):2432–2433.
25. Hochberg MC, Tive LA, Abramson SB, et al. When is osteonecrosis not osteonecrosis?: adjudication of reported serious adverse joint events in the Tanezumab clinical development program. Arthritis Rheumatol. 2016;68(2):382–391.
26. Pfizer Inc. Tanezumab arthritis Advisory Committee Briefing document; 2012. Available from: https://wayback.archive-it. org/7993/20170114000618/http://www.fda.gov/downloads/Adviso-ryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvi-soryCommittee/UCM295205.pdf. Accessed February 04, 2019.
27. Apfel SC, Schwartz S, Adornato BT, et al. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic poly-neuropathy: a randomized controlled trial. rhNGF clinical investigator group. JAMA. 2000;284(17):2215–2221.
28. Dyck PJ, Litchy WJ, Lehman KA, Hokanson JL, Low PA, O’Brien PC. Variables influencing neuropathic endpoints: the Rochester Diabetic Neuropathy Study of Healthy Subjects. Neurology. 1995;45(6):1115–1121.
29. Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and therapeutic criteria Committee of the American rheumatism association. Arthritis Rheum. 1986;29(8):1039–1049.
30. Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis. 1957;16(4):494–502.
31. Institute of Medicine. Relieving pain in America: a blueprint for transforming prevention, care, education, and research; 2011. Available from: https://www.ncbi.nlm.nih.gov/books/NBK91497/. Accessed February 04, 2019.
32. Conaghan PG, Peloso PM, Everett SV, et al. Inadequate pain relief and large functional loss among patients with knee osteoarthritis: evidence from a prospective multinational longitudinal study of osteoarthritis real-world therapies. Rheumatology (Oxford). 2015;54(2):270–277.
33. Gore M, Sadosky A, Leslie D, Tai KS, Seleznick M. Patterns of therapy switching, augmentation, and discontinuation after initiation of treatment with select medications in patients with osteoarthritis. Clin Ther. 2011;33(12):1914–1931.
34. Cannon GW. Osteoarthritis: disease burden and unmet patient needs. Available from: https://wayback.archive-it.org/7993/20170405050406/https://www.fda.gov/ohrms/dockets/ac/07/slides/2007-4290s1-02-01-Merck-Cannon.pdf. Accessed February 04, 2019.
35. American Geriatrics Society Panel on the Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. Pain Med. 2009;10(6):1062–1083.
36. Fitzcharles MA, Lussier D, Shir Y. Management of chronic arthritis pain in the elderly. Drugs Aging. 2010;27(6):471–490.
37. Krein SL, Heisler M, Piette JD, Makki F, Kerr EA. The effect of chronic pain on diabetes patients’ self-management. Diabetes Care. 2005;28(1):65–70.
38. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2): 113–130.
39. Afilalo M, Etropolski MS, Kuperwasser B, et al. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo-and active-controlled phase III study. Clin Drug Investig. 2010;30(8):489–505.
40. Bramson C, Herrmann DN, Carey W, et al. Exploring the role of tanezumab as a novel treatment for the relief of neuropathic pain. Pain Med. 2015;16(6):1163–1176.